Tanja Obradovic: Interesting statistics on the nature of licensing deals in pharmaceutics during last year
Tanja Obradovic,
“Interesting statistics on the nature of licensing deals in pharmaceutics during last year. How to interpret data showing less deals/buyers but value increasing and what it means for Biotech sector? Annual Biopharma Licensing and Venture Report by JP Morgan shows huge jump and absolute dominance of investment targeting assets within Phase II (over 4 times higher than for assets in Phase I) reflecting focus on the time point when future product potential can be assessed with increased certainty.
This is a clear signal to Biotech companies to drive critical decisions around entering clinical development and when/which product should start Phase I and driving good candidates into Phase II in order to reach strong portfolios of products and platform technologies that have a high probability of success. No wander highest number of initiated trials in 2023 was in Phase II (36.09%) far surpassing starting Phase I trials (22. 99%).
Within this environment it is increasingly critical for Biotech companies to apply strategies for efficient and accelerated early clinical development. Recent comment on Biotech survey by Chris Smyth, President of ICON Biotech, reveals some of the key areas of focus for rational drug development.
Stats for number of 2023 trials.”
Read the report.
Additional information.
Source: Tanja Obradovic/LinkedIn